Self Photos / Files - timeline_en1




Our vaccination technology has already been successfully validated by immunogenicity examination and viral challenge studies in mouse and non-human primate models. In this pipeline, we have developed a bivalent PD-1 based DNA vaccine, ICVAX, that encode for a soluble PD-1 domain fused to two chimeric HIV antigens. As a DNA vaccine, ICVAX can be repeatedly used to boost anti-HIV immune responses without issues of pre-existing immunity against vaccine vectors. We have recently completed preclincial GLP toxicity studies to domonstrate its safety. This product is currently at the pre-IND stage.



Based on our PD-1-based DNA vaccine platform, a COVID-19 DNA vaccine for SARS-CoV-2, namely ICCOV, has been constructed. Compared to non-targeting vaccines, pre-clinical tests in animal models demonstrate that ICCOV not only triggers a high level of neutralizing antibody response against multiple SARS-CoV-2 variants, but also induces a potent polyfunctional cytotoxic CD8+ T cell immune responses. More importantly, the effiacy of this vaccine against SARS-CoV-2 infection has been validated in mouse models. In collaboration with HKU, the first-in-human clinical trial of ICCOV has recently started. We are also conducting R&D on the booster vaccination strategy and the next generation ICCOV vaccine targeting SARS-CoV-2 variants.



Preclinical studies show that the IMC-003 vaccine, encoding a PD-1-linked tumour-associated antigen, provides effective control against established mesothelioma in combination with an immune checkpoint inhibitor in animal models.



IMC-004 is an antibody against a unique PD-1 isoform. Preclinical studies show that it has potential therapeutic effects against inflammatory-related diseases, including cancers. We are currently conducting drug candidate optimisation. In addition, the efficacy of IMC-004 to treat liver and colorectal cancers is being evaluated in preclinical animal models.



We are currently developing novel needleless injection systems for DNA vaccination, aiming to improve DNA vaccine efficiency and to minimise the invasiveness of electroporaion.